Clin2
NCT04282356Possibly a fitRecruiting

Test of strong chemotherapy delivered inside the abdomen

Ovarian CancerIntraperitoneal Chemotherapy

Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.

This Phase 2 trial tests an intensive treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer. It combines planned surgery to remove visible tumor with chemotherapy that is put directly inside the abdomen during the operation, aiming to control the cancer more effectively.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
55 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are 18 to 75 years old
  • Your cancer is high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (confirmed by biopsy/pathology)
  • You had a diagnostic laparoscopy that shows how widespread it is and confirms it could not be fully removed at first
  • Your cancer stage is usually IIIb/IIIc, or stage IVA with only a small-to-moderate fluid buildup around the lungs (pleural effusion less than 3 cm on CT)
  • You can have complete “interval debulking” surgery after 3 to 4 cycles of chemo, with surgery 4 to 8 weeks after the last chemo cycle
  • Your blood tests and organs function well enough for treatment (blood counts, liver, and kidneys), and you can safely receive intensive surgery

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06902467Recruiting
Chemotherapy directly into the abdomen after surgery for advanced ovarian cancer

This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.

Murcia
NCT07733505Recruiting· Phase 1
Heated chemotherapy for older women with advanced ovarian cancer

This trial tests a new way to give heated chemotherapy directly into the abdomen during surgery for women aged 70 and older with advanced ovarian cancer. It aims to find a gentler treatment option that may still be effective for those who are more frail.

Odense
NCT04847063Recruiting· Phase 1
Test drug heating inside the abdomen for peritoneal cancer

This Phase 1 trial tests a treatment that delivers heated chemotherapy directly into the abdomen (HIPEC) for certain cancers that have spread only within the abdominal lining. It aims to see how safely and effectively this approach works, especially when doctors can remove as much tumor as possible.

Bethesda, Maryland
NCT05200260Recruiting· Phase 2
Surgery plus maintenance medicines for advanced ovarian cancer

This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.

Foshan
NCT05739981Recruiting· Phase 1/Phase 2
Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer

This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.

Baltimore, Maryland
NCT07673835Not yet recruiting· Phase 2
Immunotherapy plus chemo before ovarian cancer surgery

This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this treatment shrinks the cancer more and makes surgery more effective.

Shanghai

Hear when a new Ovarian cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.